Cardiovascular Benefits of Once-a-Week GLP-1 RA Option for T2DM

Introduction

Take This Event

The discussion will covers several aspects of GLP-1 RA therapy including comparison to other first injectable therapies for T2DM, safety and efficacy of once-a-week GLP-1 RA.

Objectives

Understand increased cardiovascular Risks with Type 2 Diabetes patients.

Understand different cardiovascular trials design and patient population distribution.

Understand the difference between primary and secondary CV protection.

Understand the results of recent CV trials for Once-weekly dulaglutide and its implications on T2D patients.

See Registration Policies, Cancellations & Refunds